Trump Announces 100% Tariffs on Imported Generic Drugs Starting 2028

What Happens Next

• →U.S. domestic generic drug manufacturers attract significant capital inflows—both private equity and public market investment—to fund new API synthesis and finished-dose manufacturing facilities, with groundbreaking announcements accelerating through 2026-2027.
• →Indian pharmaceutical companies accelerate export diversification toward EU, Latin American, and African markets to offset anticipated U.S. revenue losses, compressing margins in those regions through intensified price competition.
• →U.S. generic drug prices rise 15-30% by 2029 as domestically produced generics carry higher labor, regulatory compliance, and raw material costs compared to Indian-manufactured equivalents, disproportionately impacting uninsured and underinsured populations.

Near-term: U.S. generic drug companies and hospital systems jointly lobby Congress for carve-outs on critical medicines with no domestic manufacturing capability, while pharmaceutical stocks with domestic production capacity see 10-20% valuation increases. Long-term: The global generic drug supply chain fragments into regional manufacturing blocs, with the U.S. building a parallel domestic generics industry at structurally higher cost, while India consolidates dominance in non-U.S. markets.